Home biosimilars

Keyword: biosimilars

60 results found
Copyright_jenifoto_123RF

Changes to the Public Service Health Care Plan, which took effect on July 1, include $75,000 for certain gender affirming procedures not covered by provincial or territorial health-care programs. Other new benefits include: $300 per year each for a registered dietician, occupational therapist and lactation consultant; $200 per year for batteries for hearing aids; $600 per […]

  • By: Staff
  • July 27, 2023 July 26, 2023
  • 09:00

Specialty drugs are accounting for a slightly smaller portion of the total eligible amount for all drug claims, declining from 33.6 per cent in 2021 to 33.1 per cent in 2022, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 4.6 million plan members in 2022, found the […]

  • By: Staff
  • June 14, 2023 June 15, 2023
  • 15:00
Copyright_ilixe48_123RF

An article on two upcoming executive departures at the Ontario Pension Board was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Ontario Pension Board preparing for departure of two top executives 2. Communication, education key to smooth transition to biosimilars: expert 3. 71% of Canadian employees […]

  • By: Staff
  • April 28, 2023 April 27, 2023
  • 09:00

With Yukon implementing a transitioning policy on April 3 to expand the use of biosimilar medicines in its public drug plan, it’s important for benefits plan sponsors that create a similar policy for their workplace plans to be clear in their communication and education with employees. “It’s never easy to switch a medication, especially when […]

A new diabetes treatment is expected to have the largest impact on private drug plans in 2023, according to a new report by Telus Health. The report, which analyzed more than 100 drug submissions currently under review by Health Canada, found Mounjaro, a new diabetes drug expected to become available in the first half of […]

  • By: Staff
  • March 20, 2023 March 28, 2023
  • 09:00

As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]

Copyright_dmitrydemidovich_123RF

An article on how employers can close the pension gap among BIPOC employees was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. Employers can leverage choice, education to help close pension gap among BIPOC workers 2. Ontario biosimilars policy could cut drug costs for plan […]

  • By: Staff
  • February 17, 2023 February 16, 2023
  • 09:00

Changes to Ontario’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans if they choose to follow the provincial model, says Theresa Tran, a principal in group benefits at Eckler Ltd. Starting March 31, Ontario Drug Benefit recipients who are on an originator biologic will […]

  • By: Blake Wolfe
  • February 16, 2023 February 15, 2023
  • 09:00

With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]

The increasing use of high-cost medicines is the primary cost driver for all Canadian drug plans, according to a new report by the Patented Medicine Prices Review Board. It found drug costs for public plans rose by 5.3 per cent in 2019/20, with high-cost medicines accounting for 6.3 per cent of the increase. Among private […]

  • By: Staff
  • November 25, 2022 November 24, 2022
  • 09:00